Staphylococcus Aureus Bacterin-ToxoidThis page contains information on Staphylococcus Aureus Bacterin-Toxoid for veterinary use.
The information provided typically includes the following:
- Staphylococcus Aureus Bacterin-Toxoid Indications
- Warnings and cautions for Staphylococcus Aureus Bacterin-Toxoid
- Direction and dosage information for Staphylococcus Aureus Bacterin-Toxoid
Staphylococcus Aureus Bacterin-ToxoidThis treatment applies to the following species:
Staphylococcus Aureus Bacterin-Toxoid
CA Vet. Biol. Lic. No.: 86
Contents: STAPHYLOCOCCUS AUREUS BACTERIN-TOXOID incorporates both cellular and toxoid antigens believed to be important in bovine mastitis. It utilizes a Freund's Incomplete type of oil adjuvant for maximum immune stimulation. In field trials, this vaccine has been shown to be safe for administration during lactation and pregnancy. The vaccine contains no antibiotics, so no milk withdrawal is required following vaccination of lactating animals.
Staphylococcus Aureus Bacterin-Toxoid Indications
This product is intended for use in otherwise healthy animals as an aid in the reduction of Staphylococcus aureus mastitis, in dairy cows and heifers.
Directions For Use
Administer 5 cc subcutaneously using a clean technique. Three doses spaced one month apart are recommended.
Precaution(s): Keep refrigerated at 35-47°F. Do not freeze. Shake well before using.
Entire contents of this bottle should be used when first opened.
Caution(s): This product contains an oil adjuvant. In the event of accidental self-injection, seek medical attention immediately.
Administration should be under the supervision of a licensed veterinarian. Occasionally anaphylactic or other adverse reactions may occur. If adverse reactions occur, appropriate therapy with epinephrine or other antianaphylactic drugs should be instituted immediately. Any adverse reactions following vaccination should be immediately reported to the manufacturer.
For sale in California only.
Warning(s): Do not vaccinate within 42 days of slaughter.
Discussion: Disease: Staphylococcus aureus is a gram-positive bacteria capable of causing severe mastitis and even death in susceptible dairy cows. Typically the bacteria colonize the udder and teat canal and generates a subclinical, chronic infection which responds, poorly to treatment. The reservoir of infection is the infected udder, and the organism is readily transmitted to uninfected herdmates at milking. In herds with subclinical mastitis due to Staphylococcus aureus, more than 30% of the animals may be infected. Most pathogenic strains produce toxins.
Vaccine: STAPHYLOCOCCUS AUREUS BACTERIN-TOXOID incorporates both cellular and toxoid antigens believed to be important in bovine mastitis. It utilizes a Freund's Incomplete type of oil adjuvant for maximum immune stimulation. In field trials, this vaccine has been shown to be safe for administration during lactation and pregnancy. The vaccine contains no antibiotics, so no milk withdrawal is required following vaccination of lactating animals.
Benefits: This vaccine has been shown to decrease shedding rates of Staphylococcus aureus bacteria when used according to label directions in infected animals. In controlled trials, vaccinates were significantly less likely to yield milk cultures positive for Staphylococcus aureus and showed significant improvement in milk quality by thirty days post-vaccination as shown by CMT scores. Unvaccinated control animals were four times more likely to be culled for mastitis than vaccinates.
Presentation: Available in 50 dose (250 cc) bottles.
NAC No.: 15060030
P.O. BOX 8300, WOODLAND, CA, 95776
|Lab/Main Office:||530-661-1442 (telephone)|
|Adverse Reaction Reporting:||530-661-1442 (telephone)|
|Every effort has been made to ensure the accuracy of the Staphylococcus Aureus Bacterin-Toxoid information published above. However, it remains the responsibility of the readers to familiarize themselves with the product information contained on the US product label or package insert.|
Copyright © 2017 North American Compendiums. Updated: 2017-02-06